Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM

Journal of Clinical Investigation

Volumn 111, Issue 4, 2003, Pages 487-495

  Brekken, Rolf A ^a,e   Puolakkainen, Pauli ^a,b   Graves, David C ^a   Workman, Gail ^a   Lubkin, Sharon R ^c   Sage, E Helene ^a,d  

^a HOPE HEART INSTITUTE   (United States)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEONECTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL INFILTRATION; CELL INTERACTION; EXTRACELLULAR MATRIX; MACROPHAGE; MORPHOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TUMOR GROWTH;

EID: 0037324555     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI16804     Document Type: Article

References (52)

1. Liotta, L.A., and Kohn, E.C. 2001. The microenvironment of the tumourhost interface. Nature. 411:375-379.
2. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell. 100:57-70.
3. Radisky, D., Hagios, C., and Bissell, M.J. 2001. Tumors are unique organs defined by abnormal signaling and context. Semin. Cancer Biol. 11:87-95.
4. Yeo, T.K., Brown, L., and Dvorak, H.F. 1991. Alterations in proteoglycan synthesis common to healing wounds and tumors. Am. J. Pathol. 138:1437-1450.
5. Bornstein, P., and Sage, E.H. 2002. Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol. 14:608-614.
6. Brekken, R.A., and Sage, E.H. 2001. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 19:816-827.
7. Gilmour, D.T., et al. 1998. Mice deficient for the secreted glycoprotein SPARC/osteonecrin/BM40 develop normally but show severe age-onset cataract Formation and disruption of the lens. EMBO J. 17:1860-1870.
8. Yan, Q., and Sage, E.H. 1999. SPARC, a matricellular glycoprotein with important biological functions. J. Histochem. Cytochem. 47:1495-1506.
9. Bradshaw, A.D., Reed, M.J., and Sage, E.H. 2002. SPARC null mice exhibit accelerated cutaneous wound closure. J. Histochem. Cytochem. 50:1-10.
10. Bradshaw, A.D., et al. 2001. Increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges in SPARC null mice. Wound Repair Regen. 9:522-530.
11. Ledda, M.F., et al. 1997. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med. 3:171-176.
12. Rempel, S.A., Ge, S., and Gutierrez, J.A. 1999. SPARC: a potential diagnostic marker of invasive meningiomas. Clin. Cancer Res. 5:237-241.
13. Yiu, G.K., et al. 2001. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am. J. Pathol. 159:609-622.
14. 2+-dependent binding to the extracellular matrix. J. Cell Biol. 109:341-356.
15. Carson, F.L. 1997. Histotechnology: a self-instructional text. ASCP Press. Chicago, Illinois, USA. 304 pp.
16. Andrade, G.B., Montes, G.S., Conceicao, G.M., and Saldiva, P.H. 1999. Use of the picrosirius-polarization method to age fibrotic lesions in the hepatic granulomas produced in experimental murine schistosomiasis. Ann. Trop. Med. Parasitol. 93:265-272.
17. Feng, D., et al. 2000. Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. J. Histochem. Cytochem. 48:545-556.
18. Graves, D.C., and Yablonka-Reuveni, Z. 2000. Vascular smooth muscle cells spontaneously adopt a skeletal muscle phenotype: a unique MyfS(-)/MyoD(+) myogenic program. J. Histochem. Cytochem. 48:1173-1193.
19. Brekken, R.A., et al. 2000. Selective inhibition of vascular endothelial growth Factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. 60:5117-5124.
20. 2+-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc. Natl. Acad. Sci. USA. 88:2648-2652.
21. Bradshaw, A.D., and Sage, E.H. 2001. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J. Clin. Invest. 107:1049-1054.
22. Kyriakides, T.R., et al. 1998. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J. Cell Biol. 140:419-430.
23. Koren, R., et al. 2001. Capsular collagen staining of follicular thyroid neoplasms by picrosirius red: role in differential diagnosis. Acta Histochem. 103:151-157.
24. Hallmann, R., Mayer, D.N., Berg, E.L., Broermann, R., and Butcher, E.C. 1995. Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier. Dev. Dyn. 202:325-332.
25. Gordon, S., et al. 1992. Antigen markers of macrophage differentiation in murine tissues. Curr. Top. Microbiol. Immunol. 181:1-37.
26. Ho, M.K., and Springer, T.A. 1983. Tissue distribution, structural characterization, and biosynthesis of Mac-3, a macrophage surface glycoprotein exhibiting molecular weight heterogeneity. J. Biol. Chem. 258:636-642.
27. Bradshaw, A.D., Bassuk, J.A., Francki, A., and Sage, E.H. 2000. Expression and purification of recombinant human SPARC produced by baculovirus. Mol. Cell. Biol. Res. Commun. 3:345-351.
28. Ajiro, K., Yoda, K., Utsumi, K., and Nishikawa, Y. 1996. Alteration of cell cycle-dependent histone phosphorylations by okadaic acid. Induction of mitosis-specific H3 phosphorylation and chromatin condensation in mammalian interphase cells. J. Biol. Chem. 271:13197-13201.
29. Porter, P.L., Sage, E.H., Lane, T.F., Funk, S.E., and Gown, A.M. 1995. Distribution of SPARC in normal and neoplastic human tissue. J. Histochem. Cytochem. 43:791-800.
30. Menon, P.M., Gutierrez, J.A., and Rempel, S.A. 2000. A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: high SPARC secretion correlates with decreased migration on vitronectin. Int. J. Oncol. 17:683-693.
31. Golembieski, W.A., Ge, S., Nelson, K., Mikkelsen, T., and Rempel, S.A. 1999. Increased SPARC expression promotes U87 glioblastoma invasion in vitro. Int. J. Dev. Neurosci. 17:463-472.
32. Form, D.M., VanDeWater, L., Dvorak, H.F., and Smith, B.D. 1984. Pathogenesis of tumor desmoplasia. II. Collagens synthesized by Line 1 and Line 10 guinea pig carcinoma cells and by syngeneic fibroblasts in vitro. J. Natl. Cancer Inst. 73:1207-1214.
33. Tuxhorn, J.A., et al. 2002. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res. 8:2912-2923.
34. Sasaki, T., Miosge, N., and Timpl, R. 1999. Immunochemical and tissue analysis of protease generated neoepitopes of BM-40 (osteonectin, SPARC) which are correlated to a higher affinity binding to collagens. Matrix Biol. 18:499-508.
35. Welch, M.P., Odland, G.F., and Clark, R.A. 1990. Temporal relationships of F-actin bundle formation, collagen and fibronectin matrix assembly, and fibronectin receptor expression to wound contraction. J. Cell Biol. 110:133-145.
36. Williams, D.F. 1989. A model for biocompatibility and its evaluation. J. Biomed. Eng. 11:185-191.
37. Nakanishi, H., Oguri, K., Takenaga, K., Hosoda, S., and Okayama, M. 1994. Differential fibrotic stromal responses of host tissue to low- and high-metastatic cloned Lewis lung carcinoma cells. Lab. Invest. 70:324-332.
38. Bradshaw, A.D., et al. 2003. SPARC null mice display phenotypic skin abnormalities characterized by reduced tensile strength and decreased dermal collagen fibril diameter. J. Invest. Dermatol. In press.
39. Puolakkainen, P., et al. 2003. Compromised production of extracellular matrix in mice lacking SPARC leads to reduced foreign body reaction to implanted materials. Am. J. Pathol. In press.
40. Folkman, J. 1990. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:4-6.
41. Hahnfeldt, P., Panigrahy, D., Folkman, J., and Hlatky, L. 1999. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 59:4770-4775.
42. Iruela-Arispe, M.L., et al. 1995. Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo. Mol. Biol. Cell. 6:327-343.
43. Lane, T.F., Iruela-Arispe, M.L., Johnson, R.S., and Sage, E.H. 1994. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J. Cell Biol. 125:929-943.
44. Pepper, M.S. 2001. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 21:1104-1117.
45. Elgert, K.D., Alleva, D.G., and Mullins, D.W. 1998. Tumor-induced immune dysfunction: the macrophage connection. J. Leukoc. Biol. 64:275-290.
46. Nowicki, A., et al. 1996. Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int. J. Cancer. 65:112-119.
47. Lin, E.Y., Nguyen, A.V., Russell, R.G., and Pollard, J.W. 2001. Colonystimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193:727-740.
48. Motamed, K., and Sage, E.H. 1998. SPARC inhibits endothelial cell adhesion but not proliferation through a tyrosine phosphorylation-dependent pathway. J. Cell. Biochem. 70:543-552.
49. Helmlinger, G., Netti, P.A., Lichtenbeld, H.C., Melder, R.J., and Jain, R.K. 1997. Solid stress inhibits the growth of multicellular tumor spheroids. Nat. Biotechnol. 15:778-783.
50. Lubkin, S.R., and Jackson, T. 2002. Multiphase mechanics of capsule formation in tumors. J. Biomech. Eng. 124:237-243.
51. Netti, P.A., Berk, D.A., Swartz, M.A., Grodzinsky, A.J., and Jain, R.K. 2000. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60:2497-2503.
52. Monsky, W.L., et al. 2002. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin. Cancer Res. 8:1008-1013.